Design Therapeutics Inc NASDAQ:DSGN:
DESIGN THERAPEUTICS ANNOUNCES INITIATION OF PATIENT DOSING IN PHASE 1 MULTIPLE ASCENDING DOSE TRIAL OF DT-818 FOR MYOTONIC DYSTROPHY TYPE-1
DESIGN THERAPEUTICS - EXPECTS PHASE 1 DT-818 DATA IN 2027
Reuters
Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1
- Sources
- Reuters
- Markets
- ETFs, Stocks
- Active symbols
- NASDAQ:DSGN
- Language
- English
Design Therapeutics Inc NASDAQ:DSGN: